Physician profile
Himalaya Patcha
NPI 1578516951
$1,245.24
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $147 · 2021: $81.80 · 2022: $204 · 2023: $205 · 2024: $186 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497 · Education: $17.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.66 |
| Education | $17.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $365.21 | 2019-2024 | Airsupra, Lokelma, Breztri |
| Edwards Lifesciences Corporation | $205.98 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $189.50 | 2019-2025 | Freestyle Libre 3 |
| Flowonix Medical Incorporated | $98.27 | 2020 | |
| Lundbeck LLC | $60.38 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.10 | 2019 | |
| Novo Nordisk INC | $50.10 | 2019 | |
| Valeritas, INC. | $49.50 | 2019 | |
| Abbvie INC. | $38.14 | 2023 | |
| Amarin Pharma, INC. | $37.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2022 | |
| Grifols USA, LLC | $28.18 | 2025 | Xembify |
| Janssen Pharmaceuticals, INC | $24.07 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himalaya Patcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.